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Introduction: Although standard schedule of gefitinib was the
administration of 250 mg tablet every day, many patients need dose
reduction because of toxicities. However, the efficacy of such
low-dose gefitinib for patients with epidermal growth factor recep-
tor-mutated non-small cell lung cancer has rarely been evaluated.
Methods: A post hoc comparison of the efficacy (response rate and
survival) in patients treated with gefitinib with or without any dose
reduction in NEJ002 study was performed.
Results: Among 114 patients treated with first-line gefitinib in
NEJ002, 61 (54%) continued gefitinib without any dose reduction
until their diseases progressed, and 53 (46%) reduced their dose of
gefitinib because of some toxicities. There was no significant dif-
ference of patient characteristics between the two groups. The
progression-free survival of low-dose group tended to be better than
that of standard-dose group (median progression-free survival, 11.8
versus 9.9 months; p  0.144), and the overall survival of low-dose
group was also better than that of standard-dose group (median
survival time, 32.7 versus 25.3 months; p  0.049).
Conclusions: The results suggest that low-dose gefitinib may be
clinically not inferior to standard-dose gefitinib for non-small cell
lung cancer with sensitive epidermal growth factor receptor muta-
tions. Prospective study of low-dose gefitinib is warranted especially
for frail patients who need less toxic treatment.
Key Words: Gefitinib, EGFR mutation, Low-dose, Post hoc
analysis.
(J Thorac Oncol. 2011;6: 1413–1417)
Cytotoxic chemotherapy such as carboplatin (CBDCA)plus paclitaxel (PTX) had been the standard first-line
treatment for advanced non-small cell lung cancer (NSCLC)
patients for a long time; however, its efficacy had already
reached a plateau in early 2000s, and better treatment strat-
egies have been eagerly anticipated.1,2 Gefitinib is the first
molecular-targeted agent for NSCLC and is classified as a
tyrosine kinase inhibitor of the epidermal growth factor
receptor (EGFR-TKI).3 Although gefitinib was initially ap-
proved for the entire NSCLC population, pivotal studies
published in 2004 had revealed that the presence of somatic
mutations in the kinase domain of EGFR strongly correlates
with an increased responsiveness to EGFR-TKI.4,5 Biomarker
analysis performed in Iressa Pan-Asia Study, in which effi-
cacy of gefitinib and CBDCA/PTX was compared as the
first-line treatment for NSCLC patients with favorable clini-
cal characteristics including adenocarcinoma and nonsmok-
ing history, showed a significant superiority of gefitinib in
progression-free survival (PFS) in the subset analysis for
NSCLC with mutated EGFR.6 Recently, we prospectively
demonstrated in NEJ002 phase 3 study that the first-line
gefitinib exhibited a significantly longer PFS than CBDCA/
PTX in patients with advanced NSCLC with mutated EGFR.7
According to these results, EGFR-TKI has become one of the
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standard treatments for advanced NSCLC with mutated
EGFR.
A standard dosage of gefitinib is 250 mg, which is
administered every day. Nevertheless, not a few patients need
a dose reduction of gefitinib due to toxicities including rash,
diarrhea, or liver dysfunction. Because the tablet of gefitinib
cannot be divided in half, the dose reduction is usually
achieved by changing the interval of taking the tablet from
every day to every 2 days. However, clinical evidence of such
reduced dose of gefitinib is scanty. According to some pre-
clinical data, lung cancer cell harboring sensitive EGFR
mutation are much more sensitive to EGFR-TKI than those
with wild-type EGFR.4 Therefore, we hypothesized that se-
lected patients on the basis of EGFR mutations might suffi-
ciently and safely benefit from such “low-dose” gefitinib. The
aim of this post hoc analysis from NEJ002 is to examine the
efficacy of low-dose gefitinib compared with that of standard-
dose gefitinib in EGFR-mutated NSCLC patients.
METHODS
Patient Population
We retrospectively analyzed the 114 patients treated
with gefitinib in NEJ002 study, which is a multicenter,
randomized, phase 3 trial that compared gefitinib with CBDCA/
TXL as the first-line treatment for advanced NSCLC harbor-
ing sensitive EGFR mutations. Eligibility criteria of NEJ002
included the presence of advanced NSCLC harboring sensi-
tive EGFR mutations without the resistant EGFR mutation
T790M examined by PNA-LNA polymerase chain reaction
clamp method,8 no history of chemotherapy, an age of 75
years or younger, performance status 0 to 1, appropriate
organ functions, and written informed consent.
Treatment with Gefitinib
All the patients initially received 250 mg of gefitinib
everyday according to the protocol of NEJ002. In NEJ002, a
temporary cessation of the drug administration was recom-
mended by the protocol when an intolerable toxicity such as
grade 3 or worse adverse event was observed during the
treatment with the standard dose, and a dose reduction of
gefitinib by changing the everyday schedule to every 2 days
schedule was permitted when grade 2 toxicity was observed.
In this analysis, we categorized patients into two groups
according to their treatment status as follows: standard-dose
group, in which gefitinib was administered without any dose
reductions until disease progression was observed, and low-
dose group, in which gefitinib was administered with a
reduced dose at least once during the treatment period before
disease progression (Figure 1).
Clinical Assessments
According to the protocol of NEJ002, the assessment of
antitumor response to gefitinib was performed by computed
tomography every 2 months until disease progression was
observed. Unidirectional measurements were adopted on the
basis of the Response Evaluation Criteria in Solid Tumor
(RECIST, version 1.0).9 The PFS was defined as the period
from the date of randomization to the date when disease
progression was first observed or death occurred. The re-
sponse and PFS were determined by an external review of the
computed tomography films by experts who were not aware
of the treatment assignment. Overall survival (OS) was de-
fined as the period from the date of randomization to the date
of death.
Kaplan-Meier survival curves were drawn for PFS and
OS, and differences between the groups were compared by
log-rank test. The difference in response rate was compared
by Fisher’s exact test. Each analysis was two-sided, with a
5% significance level and a 95% confidence interval, and was
performed using SAS for Windows software (release 9.1,
SAS Institute, Cary, NC).
RESULTS
Treatment
The demographics of patients in each group are listed in
Table 1. Around half of the patients in NEJ002 were catego-
rized as low-dose group. There was no significant difference
in each clinical factor and the type of EGFR mutation
between the two groups. Standard-dose group received 250
mg gefitinib for 261 days (median) (Table 2). Nine patients
temporarily suspended their treatment (median, 6 days; range,
1–32 days) due to some toxicities but restarted the treatment
with standard dose. Low-dose group received 250 mg ge-
fitinib every day for 74 days (median) and then every 2 days
for 125 days (median). Before restarting the treatment using
a reduced dose, 38 patients needed a break in their treatment
(median, 19 days; range, 2–79 days) to recover from adverse
events.
At the data cutoff point (early December 2009), 37
patients (61%) in the standard-dose group and 26 patients
(49%) in the low-dose group had stopped the first-line ge-
fitinib treatment due to disease progression, while 7 patients
(11%) in the standard-dose group and 5 patients (9%) in the
low-dose group had terminated the treatment because of
treatment-related toxicities such as interstitial lung disease
and liver dysfunction.
Efficacy
Low-dose group showed at least not-inferior efficacy
(response and survival) compared with standard-dose group.
FIGURE 1. Flowchart of the patients analyzed in this study.
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The response rate and disease control rate were 83% and 98%
in the low-dose group and 66% and 82% in standard-dose
group, respectively.
PFS for low-dose group tended to be superior to that of
standard group, although a statistical significance was not
detected. Median PFS and 1-year PFS rate were 11.8 months
and 50% in low-dose group and 9.9 months and 36% in
standard-dose group, respectively (Figure 2A). As some pa-
tients in low-dose group had switched to the low dose after a
long-term treatment with standard-dose gefitinib, we addi-
tionally investigated the efficacy of more “refined” low-dose
group (n  25) who had been treated with gefitinib at
standard dose during less than 60 days. The response rate,
median PFS, and 1-year PFS rate of the group were 83%, 7.1
months, and 27%, respectively, which was not statistically
different from those results of standard-dose group (Figure
2B). The OS was significantly longer in low-dose group than
standard-dose group (median: 32.7 versus 25.3 months; p 
0.049) (Figure 2C, Table 3).
DISCUSSION
Recent phase 3 studies including NEJ002 have sug-
gested that EGFR-TKIs are more effective than cytotoxic
chemotherapy in the first-line treatment against advanced
NSCLC with mutated EGFR.6,7,10 However, many patients
could not continuously receive standard dose of gefitinib
because of some adverse effects. In fact, about half of the
patients treated with gefitinib in NEJ002 required a dose
reduction. Therefore, treatment strategy with less toxicity is
required especially for patients with a poor condition or for
elderly patients. In this report, we demonstrated that low-dose
gefitinib may not be inferior to standard-dose gefitinib for
NSCLC patients with EGFR mutations.
Previous reports of EGFR mutations had suggested that
NSCLC cell with mutated EGFR was highly sensitive to
EGFR-TKI than those without mutations.5 Recently, Yeo et
al.11 also showed that both erlotinib and gefitinib suppressed
the proliferation of EGFR-mutated NSCLC cell lines even at
a very low concentration. Moreover, they reported a retro-
spective observation that patients treated with 25 mg of
erlotinib which was equivalent to 250 mg of gefitinib where
5 out of examined 7 patients respond to the “low-dose”
erlotinib and median PFS of those patients was 17 months.
The current study employed a larger number of patients and
supported their results that NSCLC patients with mutated
EGFR received a similar level of efficacy from low-dose
gefitinib as standard-dose gefitinib. Although low-dose ge-
fitinib in this study are considered to be much less than 25 mg
of erlotinib, twice longer half life in plasma and much higher
tumor/plasma concentration ratio of gefitinib compared with
erlotinib may favor gefitinib.12–14
There are some limitations in the current study. Be-
cause the study was a retrospective analysis, biases in patient
characteristics or undetectable factors may exist and affected
the results. From a pharmacokinetics point of view, as mean
body weight tended to be lighter in the low-dose group,
relatively higher drug concentration might be obtained in
those patients even from the low-dose gefitinib. Considering
that the OS for low-dose group was significantly longer than
that for standard-dose group, the low-dose group might in-
clude more patients with slow-growing tumor than standard-
dose group incidentally. More importantly, even for the
patients in low-dose gefitinib group, the treatment was not
initiated with low dose but with standard dose, thus the period
with standard-dose gefitinib might affect the efficacy. Al-
though the refined low-dose group still showed a similar
efficacy to standard-dose group, its small sample size cannot
draw a definite conclusion. To examine the efficacy and
safety, and appropriate treatment schedule of low-dose ge-
fitinib (e.g., initial standard dose followed by low dose versus
thoroughly low dose), prospective comparative trials should
be conducted.
In conclusion, our retrospective analysis suggests
that low-dose gefitinib may be clinically equivalent to
standard treatment with gefitinib for NSCLC with sensitive
TABLE 1. Patient Characteristics
Standard Dose Low Dose p
No. of patients 61 53
Sex
Male 27 15 0.084
Female 34 38
Mean age (range) 64 (43–75) 64 (47–75) 0.742
Mean body weight (range) 56.2 (41.1–81.6) 54.2 (34.7–93.0) 0.443
Smoking status
Never smoker 37 38 0.876
Smoker 24 15
Performance status
0/1/2 28/33/0 26/26/1 0.824
Histology
Adenocarcinoma 53 50 0.483
Others 8 3
Clinical stage
IIIB 8 7 0.805
IV 46 42
Postoperative 7 4
Type of EGFR mutation
Exon 19 deletion 27 31
L858R 27 22
Others 7 0
TABLE 2. Treatment Pattern with Gefitinib in Each Group
Standard Dose Low Dose
Given continuously n  61 n  53
Mean (SD) 287 d (211) 160 d (197)
Median (range) 261 d (14–790) 74 d (19–1153)
Given intermittently n  53
Mean (SD) — 205 d (200)
Median (range) — 125 d (7–897)
Treatment break period n  9 n  38
Mean (SD) 13 d (11) 23 d (18)
Median (range) 6 d (1–32) 19 d (2–79)
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EGFR mutations. Considering the merit of low-dose ge-
fitinib in terms of risk-benefit balance, prospective studies
using low-dose gefitinib is warranted targeting NSCLC
patients with mutated EGFR, especially elderly or those
with poor PS.
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